<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29106383</article-id>
<article-id pub-id-type="pmc">5707142</article-id>
<article-id pub-id-type="publisher-id">89885</article-id>
<article-id pub-id-type="doi">10.1172/JCI89885</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>S-sulfocysteine/NMDA receptor–dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kumar</surname>
<given-names>Avadh</given-names>
</name>
<email>akumar0@smail.uni-koeln.de</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dejanovic</surname>
<given-names>Borislav</given-names>
</name>
<email>b.dejanovic@uni-koeln.de</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hetsch</surname>
<given-names>Florian</given-names>
</name>
<email>f.hetsch@tu-braunschweig.de</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Semtner</surname>
<given-names>Marcus</given-names>
</name>
<email>marcus.semtner@mdc-berlin.de</email>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fusca</surname>
<given-names>Debora</given-names>
</name>
<email>debora.fusca@uni-koeln.de</email>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arjune</surname>
<given-names>Sita</given-names>
</name>
<email>sita.arjune@uni-koeln.de</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santamaria-Araujo</surname>
<given-names>Jose Angel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Winkelmann</surname>
<given-names>Aline</given-names>
</name>
<email>a_winkelmann@hotmail.com</email>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ayton</surname>
<given-names>Scott</given-names>
</name>
<email>scott.ayton@florey.edu.au</email>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bush</surname>
<given-names>Ashley I.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kloppenburg</surname>
<given-names>Peter</given-names>
</name>
<email>peter.kloppenburg@uni-koeln.de</email>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meier</surname>
<given-names>Jochen C.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwarz</surname>
<given-names>Guenter</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0792-8728</contrib-id>
<name>
<surname>Belaidi</surname>
<given-names>Abdel Ali</given-names>
</name>
<email>belaidia@uni-koeln.de</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Institute of Biochemistry, Department of Chemistry, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</aff>
<aff id="A2"><label>2</label>TU Braunschweig, Zoological Institute, Division of Cell Physiology, Braunschweig, Germany.</aff>
<aff id="A3"><label>3</label>Cellular Neurosciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.</aff>
<aff id="A4"><label>4</label>Biocenter, Institute for Zoology, University of Cologne, Cologne, Germany.</aff>
<aff id="A5"><label>5</label>The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.</aff>
<aff id="A6"><label>6</label>Cologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</aff>
<author-notes>
<corresp>Address correspondence to: Guenter Schwarz, Institute of Biochemistry, University of Cologne, 50674 Cologne, Germany. Phone: 49.221.470.6440; Email: <email>gschwarz@uni-koeln.de</email>. Or to: Abdel Ali Belaidi, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, Victoria 3052, Australia. Phone: 61.3.8344.8469; Email: <email>abdel.belaidi@florey.edu.au</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2017-11-06T16:00:00-0500" publication-format="electronic">
<day>6</day>
<month>11</month>
<year>2017</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2017-12-01T16:00:00-0500" publication-format="print">
<day>1</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>3</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>127</volume>
<issue>12</issue>
<fpage>4365</fpage>
<lpage>4378</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>9</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/89885">This article is available online at https://www.jci.org/articles/view/89885</self-uri>
<abstract>
<p>Molybdenum cofactor deficiency (MoCD) is an autosomal recessive inborn error of metabolism characterized by neurodegeneration and death in early childhood. The rapid and progressive neurodegeneration in MoCD presents a major clinical challenge and may relate to the poor understanding of the molecular mechanisms involved. Recently, we reported that treating patients with cyclic pyranopterin monophosphate (cPMP) is a successful therapy for a subset of infants with MoCD and prevents irreversible brain damage. Here, we studied S-sulfocysteine (SSC), a structural analog of glutamate that accumulates in the plasma and urine of patients with MoCD, and demonstrated that it acts as an <italic>N</italic>-methyl <sc>D</sc>-aspartate receptor (NMDA-R) agonist, leading to calcium influx and downstream cell signaling events and neurotoxicity. SSC treatment activated the protease calpain, and calpain-dependent degradation of the inhibitory synaptic protein gephyrin subsequently exacerbated SSC-mediated excitotoxicity and promoted loss of GABAergic synapses. Pharmacological blockade of NMDA-R, calcium influx, or calpain activity abolished SSC and glutamate neurotoxicity in primary murine neurons. Finally, the NMDA-R antagonist memantine was protective against the manifestation of symptoms in a tungstate-induced MoCD mouse model. These findings demonstrate that SSC drives excitotoxic neurodegeneration in MoCD and introduce NMDA-R antagonists as potential therapeutics for this fatal disease.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Neuroscience</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Neurodegeneration</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Center for Molecular Medicine Cologne</funding-source>
<award-id>CMMC-D5 Schwarz</award-id>
</award-group>
<funding-statement>Funding period 2011-2013</funding-statement>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>